The transcriptional modulator BCL6 as a molecular target for breast cancer therapy

Oncogene

Volumn 34, Issue 9, 2015, Pages 1073-1082

  Walker, S R ^a,b   Liu, S ^a,b   Xiang, M ^a   Nicolais, M ^a   Hatzi, K ^c   Giannopoulou, E ^c   Elemento, O ^c   Cerchietti, L ^c   Melnick, A ^c   Frank, D A ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDOMIMETIC AGENT; PROTEIN BCL 6; STAT3 PROTEIN; BCL6 PROTEIN, HUMAN; DNA BINDING PROTEIN; FEDRATINIB; PYRROLIDINE DERIVATIVE; SMALL INTERFERING RNA; SULFONAMIDE;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BINDING SITE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER SURVIVAL; CELL KILLING; CHROMATIN IMMUNOPRECIPITATION; CLONOGENIC ASSAY; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; REPRESSOR GENE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRIPLE NEGATIVE BREAST CANCER; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DRUG EFFECTS; DRUG POTENTIATION; FEMALE; GENE AMPLIFICATION; GENETICS; HIGH THROUGHPUT SEQUENCING; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

BINDING SITES; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; DNA-BINDING PROTEINS; DRUG SYNERGISM; FEMALE; GENE AMPLIFICATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MCF-7 CELLS; MOLECULAR TARGETED THERAPY; PEPTIDOMIMETICS; PYRROLIDINES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SULFONAMIDES; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84937641840     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.61     Document Type: Article

References (39)

1. Logarajah S, Hunter P, Kraman M, Steele D, Lakhani S, Bobrow L et al. BCL-6 is expressed in breast cancer and prevents mammary epithelial differentiaiton. Oncogene 2003;22:5572-5578.
2. Polo JM, Juszczynski P, Monti S, Cerchietti L, Ye K, Greally JM et al. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proc Natl Acad Sci USA 2007;104:3207-3212.
3. Ci W, Polo JM, Cerchietti L, Shaknovich R, Wang L, Yang SN et al. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood 2009;113:5536-5548.
4. Walker SR, Nelson EA, Zou L, Chaudhury M, Signoretti S, Richardson A et al. Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res 2009;7:966-976.
5. Walker SR, Nelson EA, Yeh JE, Pinello L, Yuan GC, Frank DA. STAT5 outcompetes STAT3 to regulate the expression of the oncogenic transcriptional modulator BCL6. Mol Cell Biol 2013;33:2879-2890.
6. Bos R, Van Diest PJ, Van Der Groep P, Greijer AE, Hermsen MA, Heijnen I et al. Protein expression of B-cell lymphoma gene 6 (BCL-6) in invasive breast cancer is associated with cyclin D1 and hypoxia-inducible factor-1alpha (HIF-1alpha). Oncogene 2003;22:8948-8951.
7. Polo JM, Ci W, Licht JD, Melnick A. Reversible disruption of BCL6 repression complexes by CD40 signaling in normal and malignant B cells. Blood 2008;112:644-651.
8. Ahmad KF, Melnick A, Lax S, Bouchard D, Liu J, Kiang CL et al. Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain. Mol Cell 2003;12:1551-1564.
9. Polo JM, Dell'Oso T, Ranuncolo SM, Cerchietti L, Beck D, Da Silva GF et al. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med 2004;10:1329-1335.
10. Huynh KD, Fischle W, Verdin E, BCoR Bardwell VJ. a novel corepressor involved in BCL-6 repression. Genes Dev 2000;14:1810-1823.
11. Huynh KD, Bardwell VJ. The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT. Oncogene 1998;17:2473-2484.
12. Ghetu AF, Corcoran CM, Cerchietti L, Bardwell VJ, Melnick A, Prive GG. Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer. Mol Cell 2008;29:384-391.
13. Parekh S, Polo JM, Shaknovich R, Juszczynski P, Lev P, Ranuncolo SM et al. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood 2007;110:2067-2074.
14. Fujita N, Jaye DL, Geigerman C, Akyildiz A, Mooney MR, Boss JM et al. MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation. Cell 2004;119:75-86.
15. Mendez LM, Polo JM, Yu JJ, Krupski M, Ding BB, Melnick A et al. CtBP is an essential corepressor for BCL6 autoregulation. Mol Cell Biol 2008;28:2175-2186.
16. Wang X, Li Z, Naganuma A, Ye BH. Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas. Proc Natl Acad Sci USA 2002;99:15018-15023.
17. Cerchietti LC, Yang SN, Shaknovich R, Hatzi K, Polo JM, Chadburn A et al. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood 2009;113:3397-3405.
18. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S et al. The Cancer Cell Line Encyclopediaenables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-607.
19. Bereshchenko OR, Gu W, Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet 2002;32:606-613.
20. Walker SR, Nelson EA, Frank DA. STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas. Oncogene 2007;26:224-233.
21. Welboren W-J, Van Driel MA, Janssen-Megens EM, Van Heeringen SJ, FCGJ Sweep, Span PN et al. ChIP-Seq of ER[alpha] and RNA polymerase II defines genes differentially responding to ligands. EMBO J 2009;28:1418-1428.
22. Kwon H, Thierry-Mieg D, Thierry-Mieg J, Kim H-P, Oh J, Tunyaplin C et al. Analysis of interleukin-21-induced Prdm1 gene regulation reveals functional cooperation of STAT3 and IRF4 transcription factors. Immunity 2009;31:941-952.
23. Cerchietti LC, Ghetu AF, Zhu X, Da Silva GF, Zhong S, Matthews M et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell 2010;17:400-411.
24. Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme JWalker SR et al. The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24 - stem cell-like breast cancer cells in human tumors. J Clin Invest 2011;121:2723-2735.
25. Alvarez JV, Febbo PG, Ramaswamy S, Loda M, Richardson A, Frank DA. Identification of a genetic signature of activated signal transducer and activator of transcription3 in human tumors. Cancer Res 2005;65:5054-5062.
26. Nelson EA, Walker SR, Kepich A, Gashin LB, Hideshima T, Ikeda H et al. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood 2008;112:5095-5102.
27. Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008;13:311-320.
28. Lasho TL, Tefferi A, Hood JD, Verstovsek S, Gilliland DG, Pardanani A. TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients. Leukemia 2008;22:1790-1792.
29. Fujita N, Jaye DL, Kajita M, Geigerman C, Moreno CS, Wade PA. MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell 2003;113:207-219.
30. Wang X, Belguise K, O'Neill CF, Sanchez-Morgan N, Romagnoli M, Eddy SF et al. RelB NF-kappaB represses estrogen receptor alpha expression via induction of the zinc finger protein Blimp1. Mol Cell Biol 2009;29:3832-3844.
31. Di Renzo J, Signoretti S, Nakamura N, Rivera-Gonzalez R, Sellers W, Loda M et al. Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. Cancer Res 2002;62:89-98.
32. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One 2009;4:e6146.
33. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121:2750-2767.
34. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-527.
35. Nelson EA, Walker SR, Alvarez JV, Frank DA. Isolation of unique STAT5 targets by chromatin immunoprecipitation-based gene identification. J Biol Chem 2004;279:54724-54730.
36. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol 2008;9:R137.
37. He HH, Meyer CA, Shin H, Bailey ST, Wei G, Wang Q et al. Nucleosome dynamics define transcriptional enhancers. Nat Genet 2010;42:343-347.
38. Shin H, Liu T, Manrai AK, Liu XS. CEAS: cis-regulatory element annotation system. Bioinformatics (Oxford, UK), 2009;25:2605-2606.
39. Giannopoulou EG, Elemento O. An integrated ChIP-seq analysis platform with customizable workflows. BMC Bioinform 2011;12:277.